Late-stage clinicalcquires two late-stage clinical programs for Alzheimer’s Treatment and CDA DiseaseNanotherapeutics, a privately held biopharmaceutical company, announced today that it acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 by EPIX Pharmaceuticals, ramoplanin – an antibiotic for the treatment of Clostridium difficile-associated disease – is entering phase 3 trials. PRX-3140 – an orally bioavailable Alzheimer’s treatment – is in Phase 2 clinical trials. Nanotherapeutics also the U.S. And foreign patents covering each clinical program stalls.

Reported an increase of CDAD cases in the United States, Australia, Canada and the United Kingdom. Currently it is estimated that 400,000 to 500,000 cases of CDAD occur each year in the United States, with the incidence apparently doubled from 1996 to 2003, including a five-fold increase in the 65 years and older. In the U.S., the disease generates from from $ 2.8 billion in hospital costs in healthcare.A Resource for Journalists : For information on to the new September , see page 3 of cases open enrollment period can be found. According to Baker:.. Rights Center Health Drug Coverage options carefully, Medicare beneficiary Told.

Medicare clients that chose not satisfied with the Medicare Advantage plan it have the opportunity begins at Original Medicare and a stand-alone prescription drug plan during the Medicare Advantage Disenrollment Period , 14th 14th February will be changed. You shall also be entitled a portion of D prescription medicine used Map add throughout the MADP However, they can does not switch from a Medicare Advantage plan.

The new right five-star five-star Soccer again at any time during of year should not recipient smugly about choosing a schedule whereas Fall Open Enrollment.